Reporter brief
Pilot study evaluated safety and vision effects of subconjunctival sirolimus injections in bilateral geographic atrophy
What happened
This pilot study tested whether sirolimus, injected under the outer layer of the eye, was safe and could preserve vision in patients with bilateral geographic atrophy (advanced dry AMD). Participants with visual acuity between 20/20 and 20/400 received sirolimus injections every 3 months over 2 to 3 years, with regular eye examinations, imaging, and blood tests to monitor safety and vision outcomes.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Limitations have not been recorded; consult the primary source.
Study design and sample
Other; Human.
People with geographic atrophy (GA) in both eyes with visual acuity between 20/20 and 20/400 in each eye; women of childbearing potential are eligible (implied by pregnancy testing)
- Design
- Other
- Sample
- —
- Journal
- National Eye Institute (NEI)
- Published
- Jul 14, 2020
Effect size
Not recorded.
Caveats
- Assessment: Superseded.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Rapamycin timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.